Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference

Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in non-opioid pain management solutions, has announced its participation in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference. The event is scheduled for March 11, 2026, at 2:30 PM ET in Miami. Interested parties can access live audio of the discussion via the "Events" page on the company's investor website, with a replay available for two weeks thereafter.

The company specializes in developing innovative pain relief therapies aimed at transforming patient lives without using opioids. Pacira's product lineup includes three commercial non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera®º. EXPAREL® is a long-acting local analgesic, utilized for various postsurgical pain management strategies. ZILRETTA® serves as an extended-release injectable treatment for osteoarthritis knee pain, while the iovera®º device provides immediate, drug-free pain control through targeted delivery of cold temperatures.

In addition to its commercial offerings, Pacira is advancing its pipeline of clinical-stage candidates, including the promising PCRX-201 (enekinragene inzadenovec), which is currently in Phase 2 trials for treating osteoarthritis of the knee. This aligns with the company’s commitment to advancing effective pain management solutions that minimize reliance on opioids.

For more information about Pacira BioSciences and its innovative therapies, interested individuals can visit the company's website at www.pacira.com. The upcoming events and ongoing development in their pipeline illustrate Pacira’s strategic focus on addressing complex pain management challenges in both surgical and osteoarthritis contexts, positioning the company for continued growth and impact in the healthcare landscape.

Pacira BioSciences, Inc. (NASDAQ: PCRX) presents a unique investment opportunity as it prepares to participate in the Barclays 28th Annual Global Healthcare Conference. The company's commitment to innovative, non-opioid pain therapies positions it favorably within the evolving landscape of pain management, especially as public and market demand for safe and effective alternatives to opioids continues to grow.

Pacira's portfolio includes three commercial-stage products—EXPAREL®, ZILRETTA®, and iovera®º—each targeting different pain management needs with a focus on outpatient settings. The upcoming fireside chat offers investors insight into the company's operational strategies and future directions, particularly as it advances its pipeline, including the promising PCRX-201, a gene therapy currently in Phase 2 development for knee osteoarthritis.

When evaluating Pacira as an investment, it is crucial to consider the broader context of the healthcare market, particularly the increasing emphasis on non-opioid treatments, which could give Pacira a competitive edge. The anticipated discussion at the conference may shed light on key operational updates, partnerships, or potential expansion into new markets that could drive growth.

Moreover, with a healthy cash position and the ongoing clinical advancements of non-opioid therapies, the company is well-poised to capitalize on this burgeoning sector. Investors should listen closely to the insights shared in the fireside chat, particularly related to market positioning, clinical trials outcomes, and strategic plans for product commercialization.

In summary, given Pacira's established products, innovative pipeline, and the growing market demand for opioid alternatives, the stock should be considered as a potential buy for investors seeking exposure to the healthcare sector, especially in pain management solutions. Investors are encouraged to monitor developments closely following the conference presentation.